La Jolla Pharmaceutical Company to Provide Corporate Overview at the 9th Annual JMP Securities Healthcare Conference

SAN DIEGO--()--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 9th Annual JMP Securities Healthcare Conference taking place June 24-25 in New York City.

The 9th Annual JMP Securities Healthcare Conference Presentation Details

Date:   Wednesday, June 25, 2014
Time: 2:00pm Eastern Time
Location: The Westin New York Grand Central
Webcast:

http://wsw.com/webcast/jmp24/ljpc/

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. GCS-100 currently is in Phase 2 clinical development for chronic kidney disease (CKD). LJPC-501, the Company’s second product candidate, is a natural peptide for the potential treatment of hepatorenal syndrome. LJPC-401, the Company’s third product candidate, is a natural peptide for the potential treatment of iron overload. For more information on the Company, please visit http://www.ljpc.com.

Contacts
La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
858-207-4264
GTidmarsh@ljpc.com
and
Chester S. Zygmont, III
Director of Finance
858-207-4262
czygmont@ljpc.com